research MARFATIA AWARD
The screening method effectively predicts psychosis, valproate use is linked to hair loss, and IDEAS is valid for assessing mental disorder disability.
Search
for
Sort by
Research
840-870 / 1000+ resultsresearch ISHRS Best Practices Survey Project MODULE: Anesthesia and Emergency SUMMARY ANALYSIS
research Normalized androgen ratio: its application to clinical dermatology
The normalized androgen ratio can help manage conditions with excess androgen activity in women.
research Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus
The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.
research Quality of life and psychosocial impact of scarring and non‐scarring alopecia in women
Women with scarring alopecia have a lower quality of life and more anxiety and depression than those with non-scarring alopecia.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research Dimensionality and psychometric analysis of DLQI in a Brazilian population
The DLQI is reliable but may not fully capture the impact of skin conditions on quality of life, especially in emotional and psychological areas.
research Review for "The Comparative Effects Between Long‐Term and Short‐Term Treatment of Finasteride on Anxiety‐Like and Depression‐Like Behaviors in Early Senescent Male Rats"
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss
The updated SALT II tool offers a more precise way to measure scalp hair loss.
research Anchor Scalp Reduction
Both ASR I and ASR II are effective scalp reduction techniques, with ASR I creating finer scars and ASR II removing more bald area and reducing stretch-back.
research Poster 149 Rehabilitation, Functional Status Relationship to Re‐hospitalization Rates in Patients with Hematologic Malignancy after Hematopoietic Stem Cell Transplant
Rehabilitation improved patients' mobility but did not reduce 30-day hospital readmission rates after stem cell transplants.
research Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib is effective for long-term treatment of severe alopecia areata.
research Self-Assessment examination of the American Academy of Dermatology
research Evaluation of the serum C‐reactive protein–albumin ratio and its relationship with disease severity IN alopecia areata: A prospective case–control study
CAR is a useful marker for assessing alopecia areata severity.
research Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.
research Arabic version of Skindex‐16: Translation and cultural adaptation, with assessment of reliability and validity
The Arabic Skindex-16 is a reliable and valid way to measure the impact of skin conditions on quality of life in Saudi patients.
research A COMPARISON OF THE TOXICITIES OF 4-(ETHOXYCARBOPHENYL) RETINAMIDE AND SOME OTHER RETINOIDS
4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
research Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Development and validation of a patient‐reported outcome measure for hair loss treatment: The HAIR ‐Q
The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.
research Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, CRP and ESR with disease severity in patients with alopecia areata
Higher MPV and CRP levels may indicate more severe alopecia areata.
research The Rotterdam Study: objectives and design update
The Rotterdam Study investigates diseases in older adults and has produced many research findings.
research Association Between Retinoid X Receptor Gene Variants and Dyslipidemia Risk in an Iranian Population
The rs1128977 gene variant may affect cholesterol and body measurements.
research LO-009 Responsiveness of the CLASI to alopecia and mucous membrane involvement: a retrospective study of prospectively collected data
Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research The Progressive Loss Risk Scale for Hair Restoration Surgery
The Progressive Loss Risk Scale is a system that shows the long-term risks of hair restoration surgery, which can change based on factors like age and transplant area.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research BIOACTIVE SUBSTANCE OF MEDICINAL PLANTS EFFECTIVE AGAINST HAIR LOSS
Medicinal plant substances can help prevent hair loss and improve hair health.